Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma.
Merkel cell antibody
Merkel cell carcinoma
Merkel cell polyomavirus
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
23
07
2024
accepted:
17
09
2024
medline:
7
10
2024
pubmed:
7
10
2024
entrez:
7
10
2024
Statut:
aheadofprint
Résumé
Merkel cell carcinoma (MCC) is associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV antibodies (MCPyV-Ab) in plasma correlate with survival, while MCPyV-Ab within the tumor has never been investigated. This study evaluated plasma MCPyV-Ab and tumor MCPyV-Ab titers to evaluate their role in outcomes and prognostication. A single-institution, prospective database was retrospectively reviewed for patients diagnosed with MCC from 2014 to 2021. MCPyV-Ab plasma and tumor titers, as well as patient and treatment factors, were collected. Two-year overall survival (OS) and disease-free survival (DFS) were examined based on MCPyV-Ab presence in tumor. Forty patients were identified, with a median follow-up of 27.6 months. Patients were stratified into four groups based on the presence of MCPyV-Ab in plasma (P+, P-) and tumor (T+, T-). Most patients (60.0%) were P-/T-. Of the remaining patients, 22.5% were P+/T+, 12.5% were P-/T+, and 5.0% were P+/T-. Two-year DFS of the P-/T- group was 16.6 months, which was not different from the other groups (p = 0.79). Two-year OS of P-/T- was 18.3 months, and 2-year OS of P-/T+ was 28.1 months, which was similar between groups (p = 0.80). Most patients P+ for MCPyV had antibody-positive tumors (T+), and P- patients were also T-; however, there was a subset of patients where plasma and tumor antibody findings were incongruent. Patients with MCPyV-Ab in either plasma or tumor had a trend toward improved 2-year DFS and OS, but was limited by a small cohort. This study offers an exploratory investigation into the relationship between plasma and tumor antibodies to MCPyV on which to base future work.
Sections du résumé
BACKGROUND
BACKGROUND
Merkel cell carcinoma (MCC) is associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV antibodies (MCPyV-Ab) in plasma correlate with survival, while MCPyV-Ab within the tumor has never been investigated. This study evaluated plasma MCPyV-Ab and tumor MCPyV-Ab titers to evaluate their role in outcomes and prognostication.
METHODS
METHODS
A single-institution, prospective database was retrospectively reviewed for patients diagnosed with MCC from 2014 to 2021. MCPyV-Ab plasma and tumor titers, as well as patient and treatment factors, were collected. Two-year overall survival (OS) and disease-free survival (DFS) were examined based on MCPyV-Ab presence in tumor.
RESULTS
RESULTS
Forty patients were identified, with a median follow-up of 27.6 months. Patients were stratified into four groups based on the presence of MCPyV-Ab in plasma (P+, P-) and tumor (T+, T-). Most patients (60.0%) were P-/T-. Of the remaining patients, 22.5% were P+/T+, 12.5% were P-/T+, and 5.0% were P+/T-. Two-year DFS of the P-/T- group was 16.6 months, which was not different from the other groups (p = 0.79). Two-year OS of P-/T- was 18.3 months, and 2-year OS of P-/T+ was 28.1 months, which was similar between groups (p = 0.80).
CONCLUSIONS
CONCLUSIONS
Most patients P+ for MCPyV had antibody-positive tumors (T+), and P- patients were also T-; however, there was a subset of patients where plasma and tumor antibody findings were incongruent. Patients with MCPyV-Ab in either plasma or tumor had a trend toward improved 2-year DFS and OS, but was limited by a small cohort. This study offers an exploratory investigation into the relationship between plasma and tumor antibodies to MCPyV on which to base future work.
Identifiants
pubmed: 39373930
doi: 10.1245/s10434-024-16292-8
pii: 10.1245/s10434-024-16292-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MASTT
ID : MASTT Grant at the University of Tennessee Medical
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-463.e452.
doi: 10.1016/j.jaad.2017.10.028
van Veenendaal LM, van Akkooi ACJ, Verhoef C, et al. Merkel cell carcinoma: clinical outcome and prognostic factors in 351 patients. J Surg Oncol. 2018;117(8):1768–75.
doi: 10.1002/jso.25090
Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. Adv Anat Pathol. 2009;16(3):135–44.
doi: 10.1097/PAP.0b013e3181a12f5a
Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89(1):1–4.
doi: 10.1002/jso.20167
Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49(5):832–41.
doi: 10.1016/S0190-9622(03)02108-X
Paulson KG, Lemos BD, Feng B, et al. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009;129(6):1547–55.
doi: 10.1038/jid.2008.365
Wong SQ, Waldeck K, Vergara IA, et al. UV-associated mutations underlie the etiology of MCV-negative merkel cell carcinomas. Cancer Res. 2015;75(24):5228–34.
doi: 10.1158/0008-5472.CAN-15-1877
Harms PW, Collie AM, Hovelson DH, et al. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016;29(3):240–8.
doi: 10.1038/modpathol.2015.154
Harms PW, Vats P, Verhaegen ME, et al. The distinctive mutational spectra of polyomavirus-negative merkel cell carcinoma. Cancer Res. 2015;75(18):3720–7.
doi: 10.1158/0008-5472.CAN-15-0702
Houben R, Ebert M, Hesbacher S, Kervarrec T, Schrama D. Merkel cell polyomavirus large T antigen is dispensable in G2 and M-phase to promote proliferation of merkel cell carcinoma cells. Viruses. 2020;12(10):1162.
doi: 10.3390/v12101162
Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999;8(2):153–8.
Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359(9305):497–8.
doi: 10.1016/S0140-6736(02)07668-7
Andea AA, Coit DG, Amin B, Busam KJ. Merkel cell carcinoma: histologic features and prognosis. Cancer. 2008;113(9):2549–58.
doi: 10.1002/cncr.23874
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.
doi: 10.1126/science.1152586
Houben R, Grimm J, Willmes C, Weinkam R, Becker JC, Schrama D. Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Invest Dermatol. 2012;132(1):254–6.
doi: 10.1038/jid.2011.260
Houben R, Shuda M, Weinkam R, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010;84(14):7064–72.
doi: 10.1128/JVI.02400-09
Garneski KM, Warcola AH, Feng Q, Kiviat NB, Leonard JH, Nghiem P. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129(1):246–8.
doi: 10.1038/jid.2008.229
Kassem A, Schopflin A, Diaz C, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008;68(13):5009–13.
doi: 10.1158/0008-5472.CAN-08-0949
Becker JC, Stang A, Hausen AZ, et al. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother. 2018;67(3):341–51.
doi: 10.1007/s00262-017-2099-3
Becker JC, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol. 2009;129(1):248–50.
doi: 10.1038/jid.2008.198
Laude HC, Jonchere B, Maubec E, et al. Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog. 2010;6(8):e1001076.
doi: 10.1371/journal.ppat.1001076
Paulson KG, Carter JJ, Johnson LG, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res. 2010;70(21):8388–97.
doi: 10.1158/0008-5472.CAN-10-2128
Paulson KG, Lewis CW, Redman MW, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer. 2017;123(8):1464–74.
doi: 10.1002/cncr.30475
Arroyave AJ, Lewis JM, Landry M, McLoughlin JM, Enomoto LM. Merkel cell polyomavirus antibody titer predicts recurrence-free survival. Ann Surg Oncol. 2022;29(3):1620–6.
doi: 10.1245/s10434-021-11008-8
Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog. 2009;5(9):e1000578.
doi: 10.1371/journal.ppat.1000578
Touze A, Gaitan J, Arnold F, et al. Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies. J Clin Microbiol. 2010;48(5):1767–70.
doi: 10.1128/JCM.01691-09
Touze A, Le Bidre E, Laude H, et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol. 2011;29(12):1612–9.
doi: 10.1200/JCO.2010.31.1704
Yang JF, Liu W, You J. Characterization of molecular mechanisms driving Merkel cell polyomavirus oncogene transcription and tumorigenic potential. PLoS Pathog. 2023;19(8):e1011598.
doi: 10.1371/journal.ppat.1011598
Houben R, Celikdemir B, Kervarrec T, Schrama D. Merkel cell polyomavirus: infection, genome, transcripts and its role in development of Merkel cell carcinoma. Cancers (Basel). 2023;15(2):444.
doi: 10.3390/cancers15020444
Starrett GJ, Marcelus C, Cantalupo PG, et al. Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated merkel cell carcinoma. mBio. 2017. https://doi.org/10.1128/mBio.02079-16 .
doi: 10.1128/mBio.02079-16
Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2016;7(3):3403–15.
doi: 10.18632/oncotarget.6494
Sunshine JC, Jahchan NS, Sage J, Choi J. Are there multiple cells of origin of Merkel cell carcinoma? Oncogene. 2018;37(11):1409–16.
doi: 10.1038/s41388-017-0073-3
Liu W, Yang R, Payne AS, et al. Identifying the target cells and mechanisms of Merkel cell polyomavirus infection. Cell Host Microbe. 2016;19(6):775–87.
doi: 10.1016/j.chom.2016.04.024
Nirenberg A, Steinman H, Dixon J, Dixon A. Merkel cell carcinoma update: the case for two tumours. J Eur Acad Dermatol Venereol. 2020;34(7):1425–31.
doi: 10.1111/jdv.16158
Gravemeyer J, Spassova I, Verhaegen ME, et al. DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinoma. Oncogene. 2022;41(1):37–45.
doi: 10.1038/s41388-021-02064-1
Wijaya WA, Liu Y, Qing Y, Li Z. Prevalence of merkel cell polyomavirus in normal and lesional skin: a systematic review and meta-analysis. Front Oncol. 2022;12:868781.
doi: 10.3389/fonc.2022.868781